title: AZD9668: pharmacological characterization of a novel oral inhibitor of neutrophil elastase.
abstract: N-{[5-(methanesulfonyl)pyridin-2-yl]methyl}-6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2-dihydropyridine-3-carboxamide (AZD9668) is a novel, oral inhibitor of neutrophil elastase (NE), an enzyme implicated in the signs, symptoms, and disease progression in NE-driven respiratory diseases such as bronchiectasis and chronic obstructive pulmonary disease via its role in the inflammatory process, mucus overproduction, and lung tissue damage. In vitro and in vivo experiments were done to evaluate the binding kinetics, potency, and selectivity of AZD9668, its effects in whole-blood and cell-based assays, and its efficacy in models of lung inflammation and damage. In contrast to earlier NE inhibitors, the interaction between AZD9668 and NE was rapidly reversible. AZD9668 was also highly selective for NE over other neutrophil-derived serine proteases. In cell-based assays, AZD9668 inhibited plasma NE activity in zymosan-stimulated whole blood. In isolated human polymorphonuclear cells, AZD9668 inhibited NE activity on the surface of stimulated cells and in the supernatant of primed, stimulated cells. AZD9668 showed good crossover potency to NE from other species. Oral administration of AZD9668 to mice or rats prevented human NE-induced lung injury, measured by lung hemorrhage, and an increase in matrix protein degradation products in bronchoalveolar lavage (BAL) fluid. In an acute smoke model, AZD9668 reduced the inflammatory response to cigarette smoke as indicated by a reduction in BAL neutrophils and interleukin-1β. Finally, AZD9668 prevented airspace enlargement and small airway wall remodeling in guinea pigs in response to chronic tobacco smoke exposure whether dosed therapeutically or prophylactically. In summary, AZD9668 has the potential to reduce lung inflammation and the associated structural and functional changes in human diseases.
authors.affiliation: AstraZeneca AB, Lund, Sweden.
authors.forename: T
authors.initials: T
authors.lastname: Stevens
authors.forename: K
authors.initials: K
authors.lastname: Ekholm
authors.forename: M
authors.initials: M
authors.lastname: Gränse
authors.forename: M
authors.initials: M
authors.lastname: Lindahl
authors.forename: V
authors.initials: V
authors.lastname: Kozma
authors.forename: C
authors.initials: C
authors.lastname: Jungar
authors.forename: T
authors.initials: T
authors.lastname: Ottosson
authors.forename: H
authors.initials: H
authors.lastname: Falk-Håkansson
authors.forename: A
authors.initials: A
authors.lastname: Churg
authors.forename: J L
authors.initials: JL
authors.lastname: Wright
authors.forename: H
authors.initials: H
authors.lastname: Lal
authors.forename: A
authors.initials: A
authors.lastname: Sanfridson
mesh_terms: D055371:Acute Lung Injury / Q000139:chemically induced / Q000188:drug therapy; D000818:Animals; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004646:Emphysema / Q000139:chemically induced / Q000473:pathology; D005260:Female; D005998:Glycine / Q000031:analogs & derivatives / Q000494:pharmacology; D006168:Guinea Pigs; D006801:Humans; D007700:Kinetics; D019272:Leukocyte Elastase / Q000037:antagonists & inhibitors*; D051379:Mice; D008807:Mice, Inbred BALB C; D010069:Oxadiazoles / Q000494:pharmacology; D011014:Pneumonia / Q000188:drug therapy; D011485:Protein Binding; D011728:Pyridones / Q000494:pharmacology*; D011744:Pyrimidinones / Q000494:pharmacology; D051381:Rats; D015842:Serine Proteinase Inhibitors; D013045:Species Specificity; D013379:Substrate Specificity; D013449:Sulfonamides / Q000494:pharmacology; D013450:Sulfones / Q000494:pharmacology*; D013552:Swine; D014028:Tobacco Smoke Pollution / Q000009:adverse effects
chemical_list: C419152:ONO 6818; D010069:Oxadiazoles; D011728:Pyridones; D011744:Pyrimidinones; D015842:Serine Proteinase Inhibitors; D013449:Sulfonamides; D013450:Sulfones; D014028:Tobacco Smoke Pollution; C568080:N-((5-(methanesulfonyl)pyridin-2-yl)methyl)-6-methyl-5-(1-methyl-1H-pyrazol-5-yl)-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2-dihydropyridine-3-carboxamide; C069195:sivelestat; D019272:Leukocyte Elastase; D005998:Glycine